PsychedelicNewsBreaks

TuesdayJun 22, 2021 1:18 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a human bioavailability pilot study of the Rotigotine transdermal patch for Parkinson’s Disease was completed in March 2021. Due to the favorable outcome of the study, the Rotigotine development program will be advanced to include a pivotal human trial.” The article, which documented XPhyto’s advancements so…

Continue Reading

TuesdayJun 22, 2021 10:56 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Completes 51st Pre-Clinical Psychedelic Molecule Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has completed its 51st preclinical study; the study is a critical step in the company’s progress in the Investigational New Drug (“IND”) process. The 51st study was an in-vitro and in-vivo evaluation of Cybin’s growing number of psychedelic compounds being designed and evaluated for potential therapeutic applications to treat a number of mental health situations. The announcement noted that, to date, the Cybin research and development team has evaluated more than 50 novel compounds for pharmacokinetic properties, metabolic stability, receptor binding and safety in order…

Continue Reading

MondayJun 21, 2021 11:11 am

PsychedelicNewsBreaks – Psychedelic Capital: June 2021 to Feature Top Companies, Newest Opportunities, Deep Industry Insights

Microdose Psychedelic Insights, a cutting-edge media company focused on providing content, analysis and engaging events designed to drive the psychedelics industry to the forefront of modern medicine, will be hosting the upcoming Psychedelic Capital: June 2021. The conference is slated to take place in an entirely virtual format on June 30, 2021. The event will feature some of the top companies, latest IPOs, newest opportunities, and deepest industry insights within the sector. The Psychedelic Capital conference is part of an investor conference series diving deep into psychedelic medicine investment. An introductory talk delivered by Richard Skaife, Patrick Moher and Henri…

Continue Reading

MondayJun 21, 2021 10:27 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at the Emerging Growth Conference

Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced that its CEO Doug Drysdale will be participating at the 2021 Emerging Growth Conference, which is scheduled for June 23, 2021. As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progressing psychedelic therapeutics. Drysdale’s presentation is scheduled to begin at 2 p.m. ET. Interested individuals can register to view the Cybin executive’s presentation via the webcast. Following the conference, an archived version of the presentation will be available at www.EmergingGrowth.com. To view the presentation, visit https://ibn.fm/i4DMQ To view the full press release, visit…

Continue Reading

ThursdayJun 17, 2021 10:52 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s achievements and future plans. XPhyto Therapeutics recently secured European approval and launched an effective 25-minute polymerase chain reaction (“PCR”) test for COVID-19 (“Covid-ID Lab”), with an initial focus on the German market and several other initiatives underway. “This is an exciting time for the company.…

Continue Reading

ThursdayJun 17, 2021 10:40 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Featured Guest in Latest Stock2Me Podcast

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced that chairman and CEO Greg McKee was interviewed on the most recent episode of the Stock2Me Podcast. The podcast features a fascinating array of companies and individuals that are actively revolutionizing business practices within their respective markets. In the interview, McKee talked about the objective of TRYP, which is fundamentally to help patients, as well as identifying and bringing new therapies to patients. McKee also discussed the need for innovation in the psychedelics space and Tryp’s upcoming human clinical…

Continue Reading

TuesdayJun 15, 2021 2:16 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) BC Facility Ready to Meet Increasing Demand

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) is seeing interest from producers and brands looking for new opportunities and partnerships. In a corporate update focused on three points of interest in its growing business — cannabis, functional mushrooms and psilocybin — CEO Ben Nikolaevsky noted that the company’s Pemberton, British Columbia facility is fully operational and ready to meet the increasing demand for cannabis-based gummies, vapes and white-label products. According to a recent article, “The facility will be involved as the company ramps up production on its Pure Pulls and Pure Chews as they re-enter the market. In…

Continue Reading

TuesdayJun 15, 2021 1:58 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Create Safer, More Effective Protocol in ‘Fast-Moving Arena of Psychedelic Therapies’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is collaborating with psychedelic therapy educational platform Fluence to provide design and training for the psychotherapeutic portion of its Phase 2a clinical trials for treating eating disorders and fibromyalgia. “Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider of psychotherapeutic training for health professionals that are administering psychedelic compounds to patients,” reads a recent article. The piece quotes Tryp President and Chief Science Officer Jim Gilligan as saying, “In the fast-moving arena of psychedelic therapies, Fluence has established themselves as the leader in…

Continue Reading

TuesdayJun 15, 2021 12:36 pm

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Looks to Focus Expertise on Psychedelic Drug Formulation as Manufacturing Programs Advance

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community. The audio press release discusses the company’s recent announcement regarding the status of its GMP mescaline synthesis program. “With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto's psychedelic medicine program is progressing on schedule. As the manufacturing programs advance,…

Continue Reading

MondayJun 14, 2021 1:11 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights’ Upcoming Event to Showcase the Potential of MDMA Therapeutics

Microdose Psychedelic Insights is a cutting-edge conference production company focused around promoting content, financial analysis and engaging events designed to drive the psychedelics industry into the forefront of modern medicine. In partnership with Pharmala Biotech Inc and ACS Pharmacology & Translational Science, Microdose Psychedelic Insights will host the upcoming MDMA Conference: A Molecular Masterclass in an entirely virtual format on June 15, 2021. The event will present a scientific deep dive into the dynamic field of MDMA therapeutics, exploring the potential of MDMA at the intersection of drug development and safety, clinical care and applications, law and regulation, business and…

Continue Reading